Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Published inEuropean heart journal, vol. 43, no. 8, p. 830-833
Publication date2022-02-22
Keywords
- Anticholesteremic Agents* / therapeutic use
- Cholesterol, LDL
- Drug Therapy, Combination
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
- Hypolipidemic Agents / therapeutic use
Affiliation
Funding
- Amgen and Sanofi -
Citation (ISO format)
RAY, Kausik K et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. In: European heart journal, 2022, vol. 43, n° 8, p. 830–833. doi: 10.1093/eurheartj/ehab718
Main files (1)
Article (Published version)
Identifiers
- PID : unige:161606
- DOI : 10.1093/eurheartj/ehab718
- PMID : 34636884
ISSN of the journal0195-668X